Apellis Pharmaceuticals, Inc. APLS
Analyst Consensus
Price Objectif
Analyst historical
| Analyst | Entreprise | Price during analysis | Target price | Potential gain | Publication date |
|---|---|---|---|---|---|
| Douglas Tsao | H.C. Wainwright | 27.01 $ | 57 $ | 29.99 % | 06/11/2024 |
| Colleen Kusy | Robert W. Baird | 31.7475 $ | 92 $ | 60.25 % | 23/09/2024 |
| Annabel Samimy | Stifel Nicolaus | 31.68 $ | 84 $ | 52.32 % | 20/09/2024 |
| Graig Suvannavejh | Mizuho Securities | 36.73 $ | 39 $ | 2.27 % | 20/09/2024 |
| Graig Suvannavejh | Mizuho Securities | 37.62 $ | 42 $ | 4.38 % | 16/09/2024 |
| Colleen Kusy | Robert W. Baird | 37.66 $ | 96 $ | 58.34 % | 09/08/2024 |
| Akash Tewari | Jefferies | 37.66 $ | 82 $ | 44.34 % | 08/08/2024 |
| Douglas Tsao | H.C. Wainwright | 36 $ | 83 $ | 47.00 % | 02/08/2024 |
| Colleen Kusy | Robert W. Baird | 38.88 $ | 86 $ | 47.12 % | 26/07/2024 |
| Graig Suvannavejh | Mizuho Securities | 38.36 $ | 49 $ | 10.64 % | 01/07/2024 |
| Derek Archila | Wells Fargo | 43.6 $ | 48 $ | 4.40 % | 23/05/2024 |
| Akash Tewari | Jefferies | 68.16 $ | 80 $ | 11.84 % | 05/02/2024 |
| Derek Archila | Wells Fargo | 51.71 $ | 58 $ | 6.29 % | 02/01/2023 |
| Annabel Samimy | Stifel Nicolaus | 44.53 $ | 60 $ | 15.47 % | 23/06/2022 |
| Matthew Luchini | BMO Capital | 37.34 $ | 69 $ | 31.66 % | 09/11/2021 |
| Laura Chico | Wedbush | 37.34 $ | 28 $ | -9.34 % | 09/11/2021 |
| Chris Howerton | Jefferies | 33.59 $ | 74 $ | 40.41 % | 01/10/2021 |
| Alethia Young | Cantor Fitzgerald | 33.59 $ | 74 $ | 40.41 % | 01/10/2021 |
| Tiago Fauth | Credit Suisse | 34.93 $ | 38 $ | 3.07 % | 10/09/2021 |
| Phil Nadeau | Cowen & Co. | 67.8 $ | 70 $ | 2.20 % | 01/07/2021 |